Antisense inhibition of angiotensinogen with IONIS-AGT-LRx: Results of Phase 1 and Phase 2 studies: -

Summary Targeting angiotensinogen may provide a novel approach to more optimally inhibit the RAAS pathway. Double-blind, placebo-controlled clinical trials were performed in subjects with hypertens...